MedPath

Mechanochemical Ablation vs Thermal Ablation

Not Applicable
Completed
Conditions
Varicose Veins of Lower Limb
Interventions
Procedure: EVLA
Procedure: RFA
Procedure: MOCA
Registration Number
NCT03722134
Lead Sponsor
Helsinki University Central Hospital
Brief Summary

Patients with GSV reflux were randomized to undergo either MOCA or thermal ablation with laser or radiofrequency. The main outcome measure was the occlusion rate of the GSV at one year.Patients with GSV reflux were randomized to undergo either MOCA or thermal ablation with laser or radiofrequency. The main outcome measure was the occlusion rate of the GSV at one and three years.

Detailed Description

During 2014-2015, all patients referred to our vascular surgery clinic by their general practitioners due to varicose veins were screened for GSV insufficiency. We invited all patients filling the inclusion criteria to participate in this study.

Included patients were randomized to receive either thermal ablation (laser ablation or radiofrequency ablation) or mechanochemical ablation with the Clarivein device to treat the refluxing GSV.

The patients filled the Aberdeen Varicose Veins Questionnaire (AVVQ) at the baseline. We recorded the preoperative diameter of the GSV, specifically the diameter at the most proximal 20 centimetres, and the mean overall diameter at the thigh.

During the procedure, before discharge, and a week after, the patients reported pain scores using Visual Analogue Scale (VAS) on a scale of 0 to 10. At the one-month follow-up visit, we recorded wound healing, haematomas or bruising, nerve injuries, and pigmentation. The status of the GSV was examined with duplex Doppler ultrasound. The patients were also asked to determine what would have been the optimal sick leave after the procedure.

At the one-year follow-up, nerve injuries, pigmentation, and clinical status were recorded, as well as the status of the GSV with duplex Doppler ultrasound. The patients also filled the AVVQ questionnaire.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
132
Inclusion Criteria
  • clinical classification of venous disease C2-C4
  • ultrasound-verified reflux in the GSV
  • mean GSV diameter in the thigh between 5 and 12 millimetres
  • informed consent.
Exclusion Criteria
  • body mass index (BMI) of over 40
  • peripheral arterial disease
  • lymphoedema
  • pregnancy
  • allergy to either the sclerosant or lidocaine
  • severe general illness
  • malignancy
  • previous deep venous thrombosis
  • previous varicose vein intervention in the same leg
  • coagulation disorders

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
EVLAEVLAThe refluxing GSV was treated with endovenous laser ablation.
RFARFAThe refluxing GSV was treated with radiofrequency ablation.
MOCAMOCAThe refluxing GSV was treated with ClariVein catheter (endovenous mechanochemical ablation).
Primary Outcome Measures
NameTimeMethod
Freedom from refluxfive years after the treatment

The absence of reflux in the treated great saphenous vein

Disease-specific quality of lifefive years after the treatment

Quality of life as measured by the Aberdeen Varicose Veins Questionnaire

Occlusion ratefive years after the treatment

Occlusion rate of the great saphenous vein

Secondary Outcome Measures
NameTimeMethod
Peroperative and immediate postoperative painDuring the procedure, immediately after, and at one week after the treatment

Perceived pain using Visual Analogue Scale (Range 0-10; 0=no pain; 2=Mild pain, 4=Nagging, uncomfortable pain; 6= Miserable pain; 8=Horrible pain; 10=worst possible, unbearable pain)

Sick leaveDuring the immediate postoperative period up to one month

Number of sick leave days necessary after the treatment

ComplicationsUp to five years after the treatment

All complications (deep venous thrombosis, nerve injuries, infections etc) after the treatment

Pain medicationDuring the immediate postoperative period up to one month

The amount and type of pain medication received during and after the treatment

30-day occlusion rate30 days after the treatment

The occlusion rate of the treated great saphenous vein

© Copyright 2025. All Rights Reserved by MedPath